Dr. Glaucomflecken Explains: Transdermal Estradiol in Prostate Cancer

Why It Matters

The study offers an effective, less‑toxic alternative for prostate‑cancer patients intolerant to traditional androgen deprivation, potentially reshaping treatment standards.

Key Takeaways

• Transdermal estradiol patches match LHRH agonists in metastasis‑free survival
• Estradiol reduces hot‑flash frequency compared with standard androgen deprivation
• Gynecomastia rates increase notably with transdermal estradiol therapy
• Trial published in NEJM provides level‑1 evidence for estrogen use
• Hormone‑based treatment expands urologic options beyond testosterone suppression

Summary

The video discusses a New England Journal of Medicine trial that compared transdermal estradiol patches with luteinizing hormone‑releasing hormone (LHRH) agonists in men with locally advanced prostate cancer. The study enrolled men who could not tolerate conventional androgen‑deprivation therapy and measured 3‑year metastasis‑free survival as the primary endpoint.

Results showed that estradiol was non‑inferior to LHRH agonists for metastasis‑free survival, with similar survival percentages at three years. Patients receiving the estrogen patch reported significantly fewer hot flashes, but experienced a higher incidence of gynecomastia. The trial was randomized, open‑label, and met its statistical criteria for non‑inferiority, providing robust level‑1 evidence.

The presenters framed the findings humorously as a "hormone beef" between gynecology and urology, yet emphasized the clinical relevance. One quoted line noted, "Transdermal estradiol was not inferior… with a lower incidence of hot flashes, but gynecomastia incidence was higher." The data suggest estradiol can be a viable alternative for men who struggle with standard androgen suppression.

If incorporated into practice, estradiol patches could broaden therapeutic options, reduce quality‑of‑life side effects like hot flashes, and potentially shift guideline recommendations. However, clinicians must monitor for estrogen‑related adverse events, particularly gynecomastia, when adopting this strategy.

Original Description

This video in our partnership with @DGlaucomflecken explains a trial assessing the safety and efficacy of transdermal estradiol patches in patients with prostate cancer.

View the Original Article for free: https://nej.md/DrG42

#oncology #medicaleducation #NEJM